CD2 共刺激桥接强效 CAR 诱导的细胞溶解与持久存续
CD2 costimulation bridges potent CAR-induced cytolysis and durable persistence.
CD2 胞质尾部与 CD3z 联合可提供平衡的共刺激,将快速的肿瘤减灭与 T 细胞持久性相偶联。
ALL SOURCES
CD2 costimulation bridges potent CAR-induced cytolysis and durable persistence.
CD2 胞质尾部与 CD3z 联合可提供平衡的共刺激,将快速的肿瘤减灭与 T 细胞持久性相偶联。
Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.
间皮素(MSLN)是研究最多的癌症相关抗原之一,作为治疗多种恶性肿瘤的治疗靶点被广泛研究,包括胸膜间皮瘤、胰腺导管腺癌和卵巢癌。
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
这是一项 II 期注册临床试验,评估TIL(肿瘤浸润淋巴细胞)治疗胃癌、结直肠癌、胰腺癌的安全性、可行性及初步疗效。当前状态:进行中(不再招募)。计划入组 20 例。试验地点:美国 · 匹兹堡(共 1 个中心)。登记号:NCT03935893。
Dendritic Cell-Based Immunotherapy in Patients With Resected Pancreatic Cancer.
本研究达到了主要终点,即胰腺癌患者接受SOC治疗和辅助DC免疫治疗后,胰腺切除术后的2年RFS率≥60%。这些结果值得未来开展随机试验。
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies
靶向P329G的CAR T细胞联合含P329G Fc突变的人IgG1抗原结合抗体,在不同实体瘤模型中介导了显著的体外和体内效应功能,值得进一步推进该概念的临床转化。
Preparation and anti-tumor applications of universal umbilical cord blood-derived, mesothelin-targeted CAR-T cells.
间皮素(MSLN)在超过90%的恶性胸膜间皮瘤和胰腺腺癌中过表达,而在正常组织中表达极低,因此是一个理想的免疫治疗靶点。
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
一个热门靶点是间皮素(MSLN),它在约30%的癌症表面高表达,包括间皮瘤以及卵巢癌、胰腺癌和肺癌。
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treatin
我们的结果表明,靶向靠近细胞膜的间皮素表位的 hYP218 CAR T 细胞对间皮素阳性肿瘤非常有效,并与增强的持续性和肿瘤浸润相关。
RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy.
用 hRO4 靶向 MSLN 的非脱落表位,克服了传统 MSLN 靶向疗法的关键局限。
Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
这些数据凸显了针对一组表达不同水平靶肿瘤抗原的细胞(如同人类肿瘤中的情况)评估 CAR 构建体的价值。
共 10 条
MEMBER ACCOUNT
登录成功会直接打开下一页。